🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Ultragenyx Pharmaceutical Inc. (RARE)
NASDAQ: RARE · Real-Time Price · USD
16.48
-0.74 (-4.30%)
At close: Nov 20, 2026, 4:00 PM EST
16.50
+0.02 (0.12%)
After-hours: Nov 20, 2026, 7:31 PM EST

Ultragenyx Pharmaceutical Balance Sheet

Millions USD. Fiscal year is Jan - Dec.

Assets

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Equivalents
150421174213.58132.94307.58
Short-Term Investments
116259436363.63614.82432.61
Cash & Short-Term Investments
266680610577.21747.76740.2
Cash Growth
-37.45%11.47%5.68%-22.81%1.02%-38.40%
Accounts Receivable
16615812273.3940.4528.43
Other Receivables
2231.16.416
Receivables
16816012574.4946.8544.43
Inventory
59524533.9726.7716.23
Prepaid Expenses
43463044.51-55.75
Restricted Cash
81372.010.86-
Other Current Assets
----61.66-
Total Current Assets
544951817732.18883.9856.6
Property, Plant & Equipment
231267292314.47285.73176.18
Long-Term Investments
13557135199.9148.97293.86
Goodwill
44444444.4144.4144.41
Other Intangible Assets
170176178166.27160.11130.79
Other Long-Term Assets
63373733.7922.3420.56
Total Assets
1,1871,5321,5031,4911,5451,522

Liabilities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Accounts Payable
45313942.1143.2717.14
Accrued Expenses
242265241196.49204.68145.56
Current Portion of Long-Term Debt
80695029.24--
Current Portion of Leases
-121012.611.7811.07
Current Unearned Revenue
----1.487.61
Other Current Liabilities
2274---
Total Current Liabilities
389384344280.44261.21181.37
Long-Term Debt
1,1061,147820862.33875.44351.79
Long-Term Leases
-243030.5719.8130.9
Long-Term Unearned Revenue
-----1.47
Long-Term Deferred Tax Liabilities
21303030.0631.6733.31
Other Long-Term Liabilities
40201712.214.821.01
Total Liabilities
1,5561,6051,2411,2161,193599.84

Shareholders' Equity

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Common Stock
---0.080.070.07
Additional Paid-In Capital
4,5524,4514,2133,6623,1402,997
Retained Earnings
-4,927-4,532-3,957-3,388-2,781-2,074
Treasury Stock
-10-8-4-0.43--
Comprehensive Income & Other
9931.08-6.57-1.4
Total Common Equity
-376-80255275.41352.49922.56
Minority Interest
777---
Shareholders' Equity
-369-73262275.41352.49922.56
Total Liabilities & Equity
1,1871,5321,5031,4911,5451,522

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Total Debt
1,1861,252910934.74907.03393.76
Net Cash (Debt)
-785-515-165-157.63-10.3605.37
Net Cash Growth
------26.90%
Net Cash Per Share
-7.76-5.22-1.82-2.14-0.158.93
Filing Date Shares Outstanding
101.6296.4392.582.3470.2269.38
Total Common Shares Outstanding
101.696.492.4882.3270.269.34
Working Capital
155567473451.75622.69675.24
Book Value Per Share
-3.70-0.832.763.355.0213.30
Tangible Book Value
-590-3003364.74147.98747.37
Tangible Book Value Per Share
-5.81-3.110.360.792.1110.78
Land
-171716.6216.6215.49
Buildings
-182182181.362.8-
Machinery
-125119116.2670.2854.31
Construction In Progress
----189.4576.85
Leasehold Improvements
-555858.6843.9444.08
SEC Filings: 10-K · 10-Q